Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?

被引：1
|
作者：
Saydan, Betuel [1 ]
Ozmen, Deniz [2 ]
Eskazan, Ahmet Emre [2 ]
机构：
[1] Ankara Univ, Fac Med, Ankara, Turkiye
[2] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Internal Med, Div Hematol, Istanbul, Turkiye
来源：
EXPERT REVIEW OF HEMATOLOGY | 2024年 / 17卷 / 07期
关键词：
Chronic myeloid leukemia; CML; dasatinib; low-dose; 50; mg; CHRONIC LYMPHOCYTIC-LEUKEMIA; DECISION-SUPPORT-SYSTEM; SURVIVAL; CLL; INCORPORATE; PREFERENCES; POPULATION; GUIDELINES; IBRUTINIB; LYMPHOMA;
D O I：
10.1080/17474086.2024.2370556
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：275 / 277
页数：3
相关论文
共 50 条
  • [21] The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
    Hochhaus, Andreas
    Kantarjian, Hagop
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (12) : 1971 - 1984
  • [22] Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction
    Sasaki, Koji
    Lahoti, Amit
    Jabbour, Elias
    Jain, Preetesh
    Pierce, Sherry
    Borthakur, Gautam
    Daver, Naval
    Kadia, Tapan
    Pemmaraju, Naveen
    Ferrajoli, Alessandra
    O'Brien, Susan
    Kantarjian, Hagop
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (03) : 152 - 162
  • [23] The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
    Andreas Hochhaus
    Hagop Kantarjian
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1971 - 1984
  • [24] Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia
    Masayuki Hino
    Itaru Matsumura
    Shin Fujisawa
    Kenichi Ishizawa
    Takaaki Ono
    Emiko Sakaida
    Naohiro Sekiguchi
    Yusuke Tanetsugu
    Kei Fukuhara
    Masayuki Ohkura
    Yuichiro Koide
    Naoto Takahashi
    International Journal of Hematology, 2020, 112 : 24 - 32
  • [25] Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome
    Freydman, Jessica
    Staron, Andrew
    Hughes, David
    Sloan, John M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (06) : 1489 - 1493
  • [26] Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia
    Shin, Hyejin
    Ha, Jung-Eun
    Zang, Dae Young
    Kim, Sung-Hyun
    Do, Young Rok
    Lee, Won Sik
    Kim, Dong-Wook
    Lee, Jangik, I
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (06) : E521 - E529
  • [27] Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Fallah, P.
    Amirizadeh, N.
    Poopak, B.
    Toogeh, G.
    Arefian, E.
    Kohram, F.
    Rad, S. M. A. Hosseini
    Kohram, M.
    Naghadeh, H. Teimori
    Soleimani, M.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, 37 (04) : 560 - 568
  • [28] Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase
    Michihide Tokuhira
    Yuta Kimura
    Keiji Sugimoto
    Tomonori Nakazato
    Maho Ishikawa
    Isao Fujioka
    Tomoiku Takaku
    Noriyoshi Iriyama
    Eriko Sato
    Hiroyuki Fujita
    Yoshihiro Hatta
    Norio Komatsu
    Norio Asou
    Masahiro Kizaki
    Tatsuya Kawaguchi
    Medical Oncology, 2018, 35
  • [29] Development and validation of a nomogram to predict poor efficacy of imatinib in the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients
    Li, Yuxin
    Zhang, Yilin
    Wang, Jin
    He, Aili
    Zhang, Wanggang
    Cao, Xingmei
    Chen, Yinxia
    Liu, Jie
    Zhang, Pengyu
    Wang, Jianli
    Zhao, Wanhong
    Yang, Yun
    Meng, Xin
    Chen, Sheping
    Zhang, Longjin
    Wang, Ting
    Wang, Xugeng
    Ma, Xiaorong
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [30] Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia
    Garrett, May
    Knight, Beverly
    Cortes, Jorge E.
    Deininger, Michael W.
    CANCER MEDICINE, 2023, 12 (17): : 17981 - 17992
12345